2,6-Dimethyl-2-azaspiro[3.4]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 2,6-Dimethyl-2-azaspiro[3.4]octane
• 英文别名: 2,6-dimethyl-2-azaspiro[3.4]octane
• 化学式: C₉H₁₇N
• 分子量: 139.24
• InChiKey: LSQLROHKRDYHRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS<br/>[FR] COMPOSÉS AZA BICYCLIQUES UTILISÉS COMME AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2014045031A1

  公开（公告）日：2014-03-27

  This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5, X1, X2 and p are as defined herein.

  这项发明涉及一种激动母胆碱M1受体的化合物（化学式（1）），该化合物在治疗母胆碱M1受体介导的疾病中有用。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。所提供的化合物的化学式中，R1-R5、X1、X2和p的定义如本文所述。
• [EN] OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR<br/>[FR] COMPOSÉS OXIME À UTILISER EN TANT QU'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1 ET/OU M4
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2017077292A1

  公开（公告）日：2017-05-11

  This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic Μ1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.

  这项发明涉及激动毒蕈碱M1和/或M4受体的化合物，这些化合物在治疗由毒蕈碱Μ1和M4受体介导的疾病中有用。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。所提供的化合物符合以下公式(I)，其中p；q；X1；X2；Y；R1；R2；R3；R4；R5和R6的定义如本文所述。
• [EN] SPIROCYCLIC MOLECULES AS MTH1 INHIBITORS<br/>[FR] MOLÉCULES SPIROCYCLIQUES SERVANT D'INHIBITEURS DE MTH1
  申请人：WANG ZHAOYIN

  公开号：WO2015172747A1

  公开（公告）日：2015-11-19

  Disclosed are spirocyclic compounds having MTH1 inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are useful for the treatment of abnormal cell growth, such as cancers.

  揭示了具有MTH1抑制活性的螺环化合物，以及合成和使用这类化合物的方法。优选化合物可用于治疗异常细胞生长，如癌症。
• SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS
  申请人：Wang Zhaoyin

  公开号：US20140243303A1

  公开（公告）日：2014-08-28

  The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fiuorophenyl)ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers. R 2 is selected from

  本发明涉及公式I的螺环化合物，即螺环(1H-吡唑-4-基)-3-(1-(2,6-二氯-3-氟苯基)乙氧基)吡啶-2-胺，具有蛋白激酶抑制活性，以及制备和使用这种化合物的方法。首选化合物是c-Met和/或ALK抑制剂，可用于治疗异常细胞生长，如癌症。R2从中选择。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20150232443A1

  公开（公告）日：2015-08-20

  This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R 1 -R 5 , X 1 , X 2 and p are as defined herein.

  本发明涉及化合物（式（1）），其为肌动蛋白M1受体激动剂，并且在肌动蛋白M1受体介导的疾病治疗中有用。本发明还提供了含有该化合物的药物组合物以及该化合物的治疗用途。所提供的化合物的公式为R1-R5，X1，X2和p如此定义的式（1）。